BusinessScott+Scott, Attorneys at Law, LLP Announces Investigation of Sarepta Therapeutics, Inc.By Nasdaq OMXMar 28, 2017, 3:42 PM UTC
BusinessSummit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXOct 4, 2016, 11:02 AM UTC
BusinessSarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXOct 4, 2016, 11:00 AM UTC
